Article

HDZ-740, a Potent FLT3 Inhibitor to Overcome FLT3 Mutations of Acute Myeloid Leukemia

2024-02-07

Abstract excerpt

Acute myeloid leukemia (AML) is a life-threatening cancer characterized by a five-year survival rate of less than 30%. A pivotal target for AML therapy is an activating mutation in Fms-like tyrosine kinase 3 (FLT3), known as FLT3-ITD, which has been identified as a critical factor in disease progression. Despite the clinical development of three FLT3 inhibitors, resistance to these drugs often emerges, leading to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51bf1078-3fea-591b-bb1b-ddb85d02255d
DOI: 10.21203/rs.3.rs-3925684/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HDZ-740, a Potent FLT3 Inhibitor to Overcome FLT3 Mutations of Acute Myeloid LeukemiaDOI 10.21203/rs.3.rs-3925684/v1Read

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read

Recent Advances in FLT3 Inhibitors for Acute Myeloid LeukemiaSemantic proximity Read

Discovery of the selective and efficacious inhibitors of FLT3 mutations.Semantic proximity Read

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemiaSemantic proximity Read

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read

Targeting FLT3 Mutations in Acute Myeloid LeukemiaSemantic proximity Read

Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challengesSemantic proximity Read

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 InhibitorsSemantic proximity Read

Developments and challenges of FLT3 inhibitors in acute myeloid leukemiaSemantic proximity Read